Salvarx Share Discussion Threads

[the stigologist] 16/11/2020 09:44

Interesting interview htTps://www.moneyworksmagazine.com/portage-biotech-inc-cse-pbt-u-otc-pink-ptgef/

[the stigologist] 16/11/2020 09:33

Portage Biotech Inc. (CSE: PBT.U) (OTC Pink: PTGEF) (“Portage̶1; or the “Company”;) wishes to announce that it has issued 375,014 common shares at a deemed price of US$6.64 per common share and 72,291 common share purchase warrants exercisable at a price of $6.64 per common share for a period of 2 years (collectively, the “Settlement Securities”) to settle approximately US$4.4 million of certain debt obligations and equity entitlements (the “Loan Notes”) of the Company’s wholly-owned subsidiary, SalvaRx Limited (“SalvaRx̶1;). The Loan Notes were originally issued in 2017. At that time, SalvaRx was a subsidiary of SalvaRx Group plc, a publicly listed company on the AIM board of the London Stock Exchange. Under the terms of the Loan Notes, upon the occurrence of a qualifying event, Loan Note holders would have been entitled to receive share purchase warrants of SalvaRx in addition to repayment of their Loan Note. The acquisition of SalvaRx by the Company in 2019 constituted a qualifying event. The Company has settled the Loan Note obligations of SalvaRx through the issuance of the Settlement Securities. Four of the Company’s directors, Gregory Bailey, James Mellon, Steven Mintz (in trust) and Kam Shah have received an aggregate of 363,718 common shares as they had all originally subscribed for Loan Notes in 2017 in an aggregate principal amount of approximately US$4.0 million. The issuance of the common shares to these directors is considered a related party transaction within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on appropriate exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 in respect of these issuances. Dr. Ian Walters, CEO of Portage, commented, “As a result of this transaction, the Company’s capital structure is simpler and effectively debt free, providing significant financial flexibility to further fund and expand development of innovative drugs to help cancer patients.” All Common Shares issued in connection with the Offering are subject to a minimum statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. The Common Shares issued in connection with the Offering have not been registered under the U.S. Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the United States unless registered under the Act or unless an exemption from registration is available.

[the stigologist] 12/11/2020 07:23

Very promising hTtps://www.investegate.co.uk/fastforward-inn-ltd--ffwd-/rns/investee-company-update--portage-biotech-inc-/202011120700060464F/

[the stigologist] 18/9/2020 11:58

The Intensity tweet came out after market close I don't pay too much attention to PTGEF share price It is only worth bothering with once on NASDAQ There is a reason Management want to get it on NASDAQ There is a biotech gold rush going on and you want to be part of it In an industry worth over $200bn a year (that's just cancer drugs not all Pharma) it doesn't really matter how many players there are there is a big enough and growing enough cake

[dexdringle] 18/9/2020 11:36

Hi Stig I'm still holding my Portage and these. Portage seem to be adrift in a melee of amazing potential and regulatory failings (depending who you believe). For Salvarx, I now have a share certificate for an unlisted private company of indeterminable value. Feels like there are far too many companies chasing the same pot of gold. Only one of them will get it and some of them are much larger businesses than Portage with much deeper pockets. That announcement yesterday didn't seem to do much for the Portage share price (which went down 5%?) Perhaps this will all come good - but I'm not getting too excited just in case it doesn't !!

[the stigologist] 17/9/2020 23:57

htTps://intensitytherapeutics.com/intensity-therapeutics-doses-first-patient-with-combination-of-int230-6-and-bristol-myers-squibbs-yervoy-in-a-phase-2-study/

[the stigologist] 05/7/2020 21:33

Yes. And even allowing for currency. I got a letter from Share.com post consolidation and was surprised. Haven't really kept up to date with goings on re Portage. SALV was my main play.

[bscuit] 05/7/2020 21:11

Even allowing for the consolidation?

[the stigologist] 05/7/2020 20:29

Didn't realise I had so many Portage shares. Nice surprise

[abadan2] 25/6/2020 12:22

Intensity Therapeutics Announces Publication of Research Reporting that Intratumoral Administration of INT230-6 Demonstrates Tissue Dispersive Properties, Tumor Regression and Elicits Systemic Adaptive Immunity In vivo research published in a special issue of the International Journal of Molecular Sciences WESTPORT, Conn.--(BUSINESS WIRE)-- Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced the publication of results from the Company’s nonclinical research in the International Journal of Molecular Sciences (IJMS). The paper titled, “Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models,” was published in IJMS as part of a Special Issue titled The Immune Landscape in Solid Tumors. The Special Issue addresses various aspects of the molecular and cellular biology of immune cells in the context of tumors and invites experts in the field to contribute an original research article or a comprehensive review. The paper is available online (doi.org/10.3390/ijms21124493). The paper describes the Company’s lead product candidate, INT230-6, a novel combination of cisplatin and vinblastine formulated with a unique amphiphilic diffusion enhancer molecule (SHAO) that non-covalently interacts with payloads to increase intratumoral (IT) drug dispersion when injected into solid tumors. The data reported demonstrated that INT230-6 achieved greater inhibition of tumor growth and improved survival compared to the same drugs without enhancer given intravenously or IT. INT230-6 treatment increased the number of immune infiltrating cells within injected tumors. Animals demonstrating complete responses developed systemic immunity to the cancer. INT230-6 when combined with anti-programmed cell death protein 1 (PD-1), antibodies resulted in improved survival and increased rate of complete responses. INT230-6 induced significant tumor necrosis, which induced a systemic immune-based anti-cancer attack. This research demonstrates a novel, local treatment approach for cancer that minimizes systemic toxicity while stimulating adaptive immunity. “The results reported in the paper provided the pre-clinical rationale to advance INT230-6 into clinical development,” said Lewis H. Bender Founder, President and CEO of Intensity Therapeutics and lead author on the paper. “Our clinical research conducted to-date is consistent with the results of this paper; data suggests that the dispersion, tumor-killing and immune activation properties of INT230-6 observed in mice are translating to humans. We are looking forward to initiating phase 2 clinical cohorts later this year combining INT230-6 with our partners’ products, Merck's pembrolizumab and Bristol Myers Squibb's ipilimumab, in cancers with high unmet medical need.”

[dexdringle] 17/6/2020 14:22

Never understood why SALV was kept alive with its holding of the remainder of the Portage shares. Seems totally pointless. The 'plan' to keep the listing and reverse takeover another business (or whatever) never happened so we were de-listed. I now have a useless share certificate for my holding in the now private Salvarx. Perhaps if Portage takes off, they can sell the holding, make a final cash distribution to shareholders and wind Salvarx up once and for all ?

[bscuit] 17/6/2020 13:38

100- 1 consolidation taken place

[the stigologist] 17/6/2020 13:02

Portage got more funding Jim Mellon backstopping deal

[bobby.ifa] 13/5/2020 15:41

CSE, now 16%

[bscuit] 13/5/2020 15:02

OTC or CSE?

[bobby.ifa] 13/5/2020 14:17

Portage up 12.5%, 13-13.5p

[the stigologist] 02/5/2020 23:32

Uninvestable on pink sheets or CSE in my opinion If they're going to list on Nasdaq get on on with it

[bscuit] 02/5/2020 23:27

CSE, though at present most action on OTC Pink in USA

[bobby.ifa] 19/4/2020 10:40

Are they listed on tradeable exchange?

[the stigologist] 19/4/2020 10:07

Interesting

[abadan2] 19/4/2020 09:51

Portage Biotech : provides update on portfolio company, Intensity Therapeutics, Inc. 0 04/15/2020 | 01:18pm BST TORONTO, April 15, 2020 /PRNewswire/ - (PBT.U: CSE, PTGEF: OTC Markets) - Portage Biotech Inc. ("Portage" or the "Company") wishes to provide an update on a portfolio company, Intensity Therapeutics, Inc. ("Intensity"). Portage Biotech Inc. holds an 9.7% equity interest in Intensity. Intensity signs clinical trial collaboration with Bristol Myers Squibb Intensity's collaboration with Merck reports favorable safety of INT230-6 in combination with pembrolizumab The company is launching seven phase 2 combination cohorts in solid tumors Intensity Therapeutics announced yesterday it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The program will evaluate the safety and efficacy of Intensity's lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral injection and improve immune cell recognition of cancer, when dosed in combination with Bristol Myers Squibb's Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) immune checkpoint inhibitor Yervoy® (ipilimumab). The combination will be evaluated in patients with breast cancer, liver cancer and advanced sarcoma in a series of new cohorts within IT-01, Intensity's ongoing Phase 1/2 clinical trial. Intensity will sponsor and conduct the clinical trial and Bristol Myers Squibb will supply Yervoy for use in the study. "We are pleased to share that Intensity has now partnered with Merck (previously announced on June 25th 2019) and BMS, the two leaders in the cancer immunotherapy space" said Ian B. Walters, MD, CEO of Portage and Chief Medical Officer of Intensity. Recently (March 14, 2020) Intensity also announced favorable safety from the first cohort of the Keynote A10 study (pembrolizumab/anti-PD1 plus Intensity's INT230-6). Intensity is launching into seven phase 2 programs evaluating high unmet medical need tumors types such as colorectal, pancreatic, squamous cell, bile duct, sarcoma, liver and breast cancers. The full release can be found at: hxxps://intensitytherapeutics.com/media/#media-group-press-releases So working with both Merck and BMS!

[the stigologist] 06/3/2020 00:58

it's illiquid and on an OTC exchange. Price can't be taken seriously. Intensity have been tweeting again recently though

[bscuit] 06/3/2020 00:36

P on the move? Closed up 15% @.15

[the stigologist] 25/1/2020 10:58

I'm sure we will.

[dexdringle] 25/1/2020 10:46

Will also increase the value of the Portage shares retained by the old (now delisted) Salvarx. I wonder whether we will ever get to extract our value from that?